Bristol-Myers
Squibb Company (NYSE:BMY) and BioLabs, a network of shared lab
facilities for high-potential life-science startups, located in the
nation’s key biotech innovation clusters, today announced Bristol-Myers
Squibb as the Founding Sponsor of BioLabs’ newest location,
BioLabs@NYULangone. This BioLabs site was launched in partnership with
NYU Langone Health. As part of the agreement, for each year of active
sponsorship, Bristol-Myers Squibb can nominate up to three innovative
life-sciences and biotech startup companies per year to take up
residence in BioLabs’ facilities at 180 Varick Street in Manhattan. The
nomination process will launch in early 2018.
“We are thrilled to have Bristol-Myers Squibb as Founding Sponsor in New
York, and excited to have them as part of BioLabs’ growing roster of
sponsors,” said BioLabs CEO Johannes Fruehauf, M.D., Ph.D. “Clearly,
there is a huge pent-up need for our model in The City; our sponsors are
helping make BioLabs@NYULangone the best place to start a science-based
startup in New York.”
Commenting on the Golden Ticket nomination program, he continued, “At
LabCentral in Cambridge, where Bristol-Myers Squibb Company is a
Platinum Sponsor, BMS Golden Ticket winners to date were first-time
CEOs, fresh out of academia working to move early-stage science from the
lab bench toward clinical trials. They speak regularly of the valuable
insights they have gained from interactions with Bristol-Myers Squibb.”
“Bristol-Myers Squibb is excited to sponsor BioLabs New York, which
serves as a launchpad for scientific innovation,” said Carl Decicco,
Senior Vice President and Head of Discovery at Bristol-Myers Squibb.
“The BioLabs model enables companies to advance research in a
collaborative environment, which is aligned with our focus on
accelerating discovery and development of transformational medicines for
patients with serious diseases. We’re looking forward to learning about
these emerging companies that will take up residence in the
BioLabs@NYULangone.”
“Our companies will hit the ground running as part of the largest fully
managed biotech co-working space in Manhattan,” said Nicole McKnight
Ph.D., managing director of BioLabs New York. “It’s a pleasure to work
with the Bristol-Myers Squibb team to bring this project to fruition.”
A Golden Ticket represents one underwritten bench space per year for one
scientist at BioLabs, and a priority spot on the waiting list. The
Golden Ticket also promotes collaboration among sponsors and the
start-up companies; the program provides sponsors with early access to
potentially transformational targets and technology, and the start-ups
with the mentorship of their sponsor teams.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
YouTube
and Facebook.
About BioLabs and BioLabs New York (
www.BioLabs.io
twitter:
@BioLabsHQ
@BioLabsNY
BioLabs is a membership-based network of shared lab facilities located
in the nation’s key biotech innovation clusters, designed exclusively
for high-potential, early-stage life science companies. It offers
coworking environments that pair premium, fully equipped and supported
lab and office space with unparalleled access to capital and industry
partners. This fertile, supportive ecosystem allows nascent companies to
shift their focus from startup operations to innovation so they can
reach their scientific potential quickly and achieve business success.
Companies can start with a single bench, and scale up as they grow.
BioLabs’ founding site is in Kendall Square, Cambridge, Massachusetts,
with additional locations in North Carolina; San Diego, California; and
opening in New York City, BioLabs@NYULangone.
Partner sites include LabCentral
in Kendall Square, and QB3@953
in San Francisco, California.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb's
business, particularly those identified in the cautionary factors
discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the
year ended December 31, 2016 in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Bristol-Myers Squibb Company Media: Chrissy Trank, 609-252-5609 Christina.trank@bms.com or Investors: Tim Power, 609-252-7509 timothy.power@bms.com orBill Szablewski, 609-252-5894 william.szablewski@bms.com or BioLabs Caroline Grossman, 781-771-5579 caroline@biolabs.io